Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase

You may be eligible if

• Any patient 16 years of age or older with measurable metastatic melanoma who has failed standard treatment and has an expected survival of greater than three months.
• Must be HLA-A0201.
• Serum creatinine of 2.0 mg/dl or less.
• Bilirubin 1.6 mg/dl or less.
• WBC 3000/mm(3) or greater.
• Platelet count 90,000 mm(3) or greater.
• Serum AST/ALT less then two times normal.
• ECOG performance status of 0 or 1.
• Patients of both genders must be willing to practice effective birth control during the trial.
• Must not be undergoing or have undergone in the past 3 weeks any other form of therapy except surgery for their cancer.
• Must not have active systemic infections, coagulation disorders, or other major medical illnesses of the cardiovascular or respiratory systems or any known immunodeficiency disease.
• Must not require steroid therapy.
• Must not be pregnant.
• Must not be positive for hepatitis B(s)AG or HIV antibody.
• Must not have had a known allergic reaction to Incomplete Freund's Adjuvant (IFA).